vs
ESCO TECHNOLOGIES INC（ESE）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
ESCO TECHNOLOGIES INC的季度营收约是Ultragenyx Pharmaceutical Inc.的1.4倍（$289.7M vs $207.3M），ESCO TECHNOLOGIES INC净利率更高（9.9% vs -62.0%，领先71.9%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 17.3%），ESCO TECHNOLOGIES INC自由现金流更多（$63.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 7.8%）
ESCO是来自新加坡的品牌，专注于实验室领域相关产品及服务的研发、生产与销售，可为各类科研、检测及工业实验室提供适配的产品解决方案与配套支持，产品广泛应用于生命科学、医疗健康、工业检测等多个领域。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
ESE vs RARE — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $289.7M | $207.3M |
| 净利润 | $28.7M | $-128.6M |
| 毛利率 | 41.4% | — |
| 营业利润率 | 13.2% | -54.7% |
| 净利率 | 9.9% | -62.0% |
| 营收同比 | 17.3% | 25.9% |
| 净利润同比 | 22.2% | 3.5% |
| 每股收益（稀释后） | $1.11 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $289.7M | $207.3M | ||
| Q3 25 | $286.5M | $159.9M | ||
| Q2 25 | $296.3M | $166.5M | ||
| Q1 25 | $265.5M | $139.3M | ||
| Q4 24 | $247.0M | $164.6M | ||
| Q3 24 | $298.5M | $139.5M | ||
| Q2 24 | $260.8M | $147.0M | ||
| Q1 24 | $249.1M | $108.8M |
| Q4 25 | $28.7M | $-128.6M | ||
| Q3 25 | $218.7M | $-180.4M | ||
| Q2 25 | $26.1M | $-115.0M | ||
| Q1 25 | $31.0M | $-151.1M | ||
| Q4 24 | $23.5M | $-133.2M | ||
| Q3 24 | $34.3M | $-133.5M | ||
| Q2 24 | $29.2M | $-131.6M | ||
| Q1 24 | $23.2M | $-170.7M |
| Q4 25 | 41.4% | — | ||
| Q3 25 | 45.9% | — | ||
| Q2 25 | 41.2% | — | ||
| Q1 25 | 41.1% | — | ||
| Q4 24 | 39.8% | — | ||
| Q3 24 | 40.1% | — | ||
| Q2 24 | 39.6% | — | ||
| Q1 24 | 38.8% | — |
| Q4 25 | 13.2% | -54.7% | ||
| Q3 25 | 17.2% | -106.9% | ||
| Q2 25 | 11.2% | -64.8% | ||
| Q1 25 | 15.3% | -102.6% | ||
| Q4 24 | 11.4% | -74.3% | ||
| Q3 24 | 14.8% | -94.6% | ||
| Q2 24 | 14.3% | -79.1% | ||
| Q1 24 | 11.7% | -151.9% |
| Q4 25 | 9.9% | -62.0% | ||
| Q3 25 | 76.3% | -112.8% | ||
| Q2 25 | 8.8% | -69.0% | ||
| Q1 25 | 11.7% | -108.5% | ||
| Q4 24 | 9.5% | -80.9% | ||
| Q3 24 | 11.5% | -95.7% | ||
| Q2 24 | 11.2% | -89.5% | ||
| Q1 24 | 9.3% | -156.8% |
| Q4 25 | $1.11 | $-1.28 | ||
| Q3 25 | $8.43 | $-1.81 | ||
| Q2 25 | $1.01 | $-1.17 | ||
| Q1 25 | $1.20 | $-1.57 | ||
| Q4 24 | $0.91 | $-1.34 | ||
| Q3 24 | $1.32 | $-1.40 | ||
| Q2 24 | $1.13 | $-1.52 | ||
| Q1 24 | $0.90 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $103.8M | $421.0M |
| 总债务越低越好 | $145.5M | — |
| 股东权益账面价值 | $1.6B | $-80.0M |
| 总资产 | $2.4B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.09× | — |
8季度趋势，按日历期对齐
| Q4 25 | $103.8M | $421.0M | ||
| Q3 25 | $101.3M | $202.5M | ||
| Q2 25 | $78.7M | $176.3M | ||
| Q1 25 | $57.4M | $127.1M | ||
| Q4 24 | $71.3M | $174.0M | ||
| Q3 24 | $66.0M | $150.6M | ||
| Q2 24 | $63.0M | $480.7M | ||
| Q1 24 | $59.4M | $112.3M |
| Q4 25 | $145.5M | — | ||
| Q3 25 | $186.0M | — | ||
| Q2 25 | $525.0M | — | ||
| Q1 25 | $88.0M | — | ||
| Q4 24 | $112.0M | — | ||
| Q3 24 | $122.0M | — | ||
| Q2 24 | $173.0M | — | ||
| Q1 24 | $191.0M | — |
| Q4 25 | $1.6B | $-80.0M | ||
| Q3 25 | $1.5B | $9.2M | ||
| Q2 25 | $1.3B | $151.3M | ||
| Q1 25 | $1.3B | $144.2M | ||
| Q4 24 | $1.2B | $255.0M | ||
| Q3 24 | $1.2B | $346.8M | ||
| Q2 24 | $1.2B | $432.4M | ||
| Q1 24 | $1.2B | $140.3M |
| Q4 25 | $2.4B | $1.5B | ||
| Q3 25 | $2.4B | $1.2B | ||
| Q2 25 | $2.5B | $1.3B | ||
| Q1 25 | $1.8B | $1.3B | ||
| Q4 24 | $1.8B | $1.5B | ||
| Q3 24 | $1.8B | $1.5B | ||
| Q2 24 | $1.8B | $1.6B | ||
| Q1 24 | $1.8B | $1.3B |
| Q4 25 | 0.09× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | 0.07× | — | ||
| Q4 24 | 0.09× | — | ||
| Q3 24 | 0.10× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.16× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $68.9M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $63.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 21.7% | -48.6% |
| 资本支出强度资本支出/营收 | 2.0% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.40× | — |
| 过去12个月自由现金流最近4个季度 | $239.6M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $68.9M | $-99.8M | ||
| Q3 25 | $109.9M | $-91.4M | ||
| Q2 25 | $73.7M | $-108.3M | ||
| Q1 25 | $24.1M | $-166.5M | ||
| Q4 24 | $34.2M | $-79.3M | ||
| Q3 24 | $72.1M | $-67.0M | ||
| Q2 24 | $36.2M | $-77.0M | ||
| Q1 24 | $10.5M | $-190.7M |
| Q4 25 | $63.0M | $-100.8M | ||
| Q3 25 | $97.8M | $-92.7M | ||
| Q2 25 | $64.9M | $-110.7M | ||
| Q1 25 | $14.0M | $-167.8M | ||
| Q4 24 | $29.0M | $-79.5M | ||
| Q3 24 | $60.9M | $-68.6M | ||
| Q2 24 | $27.6M | $-79.0M | ||
| Q1 24 | $2.0M | $-193.9M |
| Q4 25 | 21.7% | -48.6% | ||
| Q3 25 | 34.1% | -58.0% | ||
| Q2 25 | 21.9% | -66.5% | ||
| Q1 25 | 5.3% | -120.5% | ||
| Q4 24 | 11.7% | -48.3% | ||
| Q3 24 | 20.4% | -49.2% | ||
| Q2 24 | 10.6% | -53.7% | ||
| Q1 24 | 0.8% | -178.2% |
| Q4 25 | 2.0% | 0.5% | ||
| Q3 25 | 4.2% | 0.8% | ||
| Q2 25 | 3.0% | 1.5% | ||
| Q1 25 | 3.8% | 1.0% | ||
| Q4 24 | 2.1% | 0.1% | ||
| Q3 24 | 3.8% | 1.2% | ||
| Q2 24 | 3.3% | 1.4% | ||
| Q1 24 | 3.4% | 3.0% |
| Q4 25 | 2.40× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 2.83× | — | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | 2.10× | — | ||
| Q2 24 | 1.24× | — | ||
| Q1 24 | 0.45× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESE
| US Government | $98.0M | 34% |
| Utility Solutions Group | $87.5M | 30% |
| RF Shielding And Test | $58.3M | 20% |
| Commercial | $45.8M | 16% |
| Related Party | $1.3M | 0% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
